Search Result

Results for "

large intestine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Intermediate (1) Endogenous Metabolite (1) Interleukin Related (1) Potassium Channel (1) TET Protein (1) TNF Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126360

Oxazolone	TNF Receptor Interleukin Related	Inflammation/Immunology
Oxazolone is a haptenizing agent that induces acute or chronic inflammation of the large intestine and is used to construct models of colitis. Oxazolone can cause Th1/Th2-dependent colitis with weight loss and diarrhea. Oxazolone-induced inflammation can be mitigated by neutralizing anti-IL-4 or anti-TNF-α antibodies or decoy IL-13R2-α-FC proteins .

HY-129878

N-Trifluoroacetyladriamycin AD-41	Endogenous Metabolite	Cancer
N-Trifluoroacetyladriamycin (AD-41) is a chemotherapeutic compound with antitumor activity. N-Trifluoroacetyladriamycin exhibits the highest fluorescence and radioactivity levels in the small intestine and liver, indicating its significant accumulation in these tissues. N-Trifluoroacetyladriamycin also shows significant accumulation in the kidney, spleen, large intestine, lung, and heart. N-Trifluoroacetyladriamycin is a metabolite of Valrubicin, which is used to inhibit bladder cancer. The presence of N-Trifluoroacetyladriamycin and its derivatives may be related to the biotransformation of the compound and its antitumor mechanism .

HY-W094747A

Benzalazine	Drug Intermediate	Inflammation/Immunology
Benzalazine is a 5-azo derivative of 5-Aminosalicylic Acid (HY-15027) that can be used for the research of ulcerative colitis and Crohn's disease of the large intestine. The benzalazine metabolite 5-ASA and the 5-ASA metabolite acetyl-5-aminosalicylic acid are excreted mainly with the faeces .

HY-W396714

Succinic acid sodium Wormwood acid sodium	Potassium Channel TET Protein	Cardiovascular Disease Neurological Disease
Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	2,024 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,024 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

2,024 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,024 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.